Prostate Cancer News and Research

Latest Prostate Cancer News and Research

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

1 Sep 2012

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for ZYTIGA (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.

30 Aug 2012

Book guides men with prostate cancer to maintain sexual health and quality of life

Men with prostate cancer may fear that they will never have sex again. What they are feeling can be disturbing, but there is hope. Jeffrey Albaugh, PhD, APRN, CUCNS, addresses sexual issues during and after prostate cancer treatment in a new book written specifically for patients and their partners: Reclaiming Sex & Intimacy After Prostate Cancer: A Guide for Men and Their Partners.

30 Aug 2012

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.

30 Aug 2012

Researchers identify mechanism that explains link between trichomoniasis and prostate cancer

Researchers have identified a way in which men can develop prostate cancer after contracting trichomoniasis, a curable but often overlooked sexually transmitted disease.

30 Aug 2012

Physicians’ emotional, institutional barriers prolong medical futility at end of life

The most common reasons that clinicians give to explain medically futile treatment at the end of life are emotional difficulties, such as a fear of talking about death, and institutional barriers, such as hospital departments expecting them to “do everything possible,” report German researchers.

29 Aug 2012

Anova Cancer Care to participate in CyberKnife research study

Anova Cancer Care has been chosen to participate in a landmark national prostate cancer study. The goal of the two-year study is to determine the best treatments for prostate cancer. The study will look specifically at prostate cancer radiosurgery.

29 Aug 2012

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

Acorda Therapeutics, Inc. announced data from a preclinical study showed that treatment with Glial Growth Factor 2 (GGF2) improved erectile function in an animal model following a cavernous nerve (CN) injury, a common complication of prostate surgery.

29 Aug 2012

Taking aspirin associated with reduced risk of death from prostate cancer

Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, says a new study that includes a researcher at UT Southwestern Medical Center.

29 Aug 2012

Eplerenone shown to reduce cumulative heart failure hospitalisations

Pfizer Inc. (NYSE: PFE) announced results from a new post-hoc analysis of the EMPHASIS-HF trial showing statistically significant reductions in rates of cumulative heart failure (HF) hospitalisations in patients with HF treated with eplerenone compared with placebo on a background of standard optimal therapy.1 The results were presented at The European Society of Cardiology Congress (ESC) in Munich.

28 Aug 2012

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced that the first patient has been enrolled in an open-label phase III study to investigate the efficacy, safety, and pharmacokinetics of the sustained release triptorelin pamoate 22.5 mg 6-month-formulation in children with central precocious puberty (CPP), a rare disease.

27 Aug 2012

Research roundup: Who do patients seek for primary care?; Treating kids with antipsychotics

n order to find out what kind of doctor patients were visiting for primary care service, researchers analyzed the frequency in which patients visited generalists and specialists in 1999 and 2007 by using a nationally representative sample of outpatient visits.

26 Aug 2012

Survival rate for African-American men with prostate cancer now comparable to Caucasians

The routine use of prostate specific antigen (PSA) testing for screening and monitoring prostate cancer has led to early and more sensitive detection of the disease. A new study published in The Journal of Urology- reports that in the "PSA era," survival has improved for patients with newly diagnosed prostate cancer that has spread to the bones or other parts of the body and the disparity between African American and Caucasian men has been resolved.

24 Aug 2012

Study shows how cancer survival rates developed in West Germany

Data from the 1970s and 1980s show that people affected by cancer survived significantly longer in West Germany than cancer patients behind the Iron Curtain.

24 Aug 2012

Racial differences persist in prostate cancer surgical care

A study led by investigators from Vanderbilt-Ingram Cancer Center (VICC), Nashville, Tenn., finds that black men with prostate cancer receive lower quality surgical care than white men. The racial differences persist even when controlling for factors such as the year of surgery, age, comorbidities and insurance status.

24 Aug 2012

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Northwest Biotherapeutics announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, for the Company's 300-patient Phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K.

24 Aug 2012

Fizzy tablet is best method to receive fentanyl for cancer pain

Results of a mixed treatment comparison show that fentanyl in the form of an effervescent buccal tablet can better relieve the intensity of breakthrough cancer pain in the first 60 minutes after dosing compared with other fentanyl formulations.

23 Aug 2012

Six common myths about prostate cancer

When it comes to prostate cancer, there's a lot of confusion about how to prevent it, find it early and the best way - or even whether - to treat it. Below are six common prostate cancer myths along with research-based information from scientists at Fred Hutchinson Cancer Research Center to help men separate fact from fiction.

23 Aug 2012

‘Sitting service’ at end of life may improve chances of dying at home

Individuals at the end of their life who use a sitting service to avoid being alone while dying or to give respite to family members who are caring for them, are significantly more likely to die at home than those who do not use such a service, report researchers.

22 Aug 2012

Viewpoints: Insuring medical treatments are well researched; GOP Govs reluctance on exchanges may backfire

By 1990, many doctors were recommending hormone replacement therapy to healthy middle-aged women and P.S.A. screening for prostate cancer to older men. Both interventions had become standard medical practice. But in 2002, a randomized trial showed that preventive hormone replacement caused more problems (more heart disease and breast cancer) than it solved. ... Then, in 2009, trials showed that P.S.A. screening led to many unnecessary surgeries and had a dubious effect on prostate cancer deaths.

21 Aug 2012

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Book guides men with prostate cancer to maintain sexual health and quality of life

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Researchers identify mechanism that explains link between trichomoniasis and prostate cancer

Physicians’ emotional, institutional barriers prolong medical futility at end of life

Anova Cancer Care to participate in CyberKnife research study

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

Taking aspirin associated with reduced risk of death from prostate cancer

Eplerenone shown to reduce cumulative heart failure hospitalisations

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

Research roundup: Who do patients seek for primary care?; Treating kids with antipsychotics

Survival rate for African-American men with prostate cancer now comparable to Caucasians

Study shows how cancer survival rates developed in West Germany

Racial differences persist in prostate cancer surgical care

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Fizzy tablet is best method to receive fentanyl for cancer pain

Six common myths about prostate cancer

‘Sitting service’ at end of life may improve chances of dying at home

Viewpoints: Insuring medical treatments are well researched; GOP Govs reluctance on exchanges may backfire

What to know about prostate cancer eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in